206 related articles for article (PubMed ID: 11252340)
1. Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia.
Contini C; Angelici E; Canipari R
J Antimicrob Chemother; 1999 Feb; 43(2):301-4. PubMed ID: 11252340
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii.
Cirioni O; Giacometti A; Balducci M; Burzacchini F; Scalise G
J Antimicrob Chemother; 1995 Oct; 36(4):740-2. PubMed ID: 8591953
[No Abstract] [Full Text] [Related]
3. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
[TBL] [Abstract][Full Text] [Related]
4. Employment of terbinafine against Pneumocystis carinii infection in rat models.
Contini C; Colombo D; Cultrera R; Prini E; Sechi T; Angelici E; Canipari R
Br J Dermatol; 1996 Jun; 134 Suppl 46():30-2; discussion 40. PubMed ID: 8763466
[TBL] [Abstract][Full Text] [Related]
5. Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.
Hughes WT; Sillos EM; LaFon S; Rogers M; Woolley JL; Davis C; Studenberg S; Pattishall E; Freeze T; Snyder G; Staton S
J Infect Dis; 1998 Apr; 177(4):1046-56. PubMed ID: 9534981
[TBL] [Abstract][Full Text] [Related]
6. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
7. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
Kovacs JA; Gill VJ; Meshnick S; Masur H
JAMA; 2001 Nov; 286(19):2450-60. PubMed ID: 11712941
[TBL] [Abstract][Full Text] [Related]
8. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.
Walzer PD; Ashbaugh A
Antimicrob Agents Chemother; 2002 Feb; 46(2):514-6. PubMed ID: 11796365
[TBL] [Abstract][Full Text] [Related]
9. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery.
Lasbury ME; Durant PJ; Bartlett MS; Smith JW; Lee CH
Clin Diagn Lab Immunol; 2003 Mar; 10(2):293-302. PubMed ID: 12626457
[TBL] [Abstract][Full Text] [Related]
10. Application of immunoblotting to detect soluble Pneumocystis carinii antigen(s) in bronchoalveolar lavage of patients with Pneumocystis pneumonia and AIDS.
Sethi KK
J Clin Pathol; 1990 Jul; 43(7):584-6. PubMed ID: 2380406
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
12. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia.
Hughes WT; LaFon SW; Scott JD; Masur H
J Infect Dis; 1995 May; 171(5):1295-301. PubMed ID: 7751706
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Pneumocystis carinii organism burden, viability and antigens in bronchoalveolar lavage fluid in AIDS patients with pneumocystosis: correlation with disease severity.
Smulian AG; Linke MJ; Cushion MT; Baughman RP; Frame PT; Dohn MN; White ML; Walzer PD
AIDS; 1994 Nov; 8(11):1555-62. PubMed ID: 7531457
[TBL] [Abstract][Full Text] [Related]
14. Atovaquone: a new antipneumocystis agent.
Artymowicz RJ; James VE
Clin Pharm; 1993 Aug; 12(8):563-70. PubMed ID: 8222520
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis carinii organisms obtained from rats, ferrets, and mice are antigenically different.
Bauer NL; Paulsrud JR; Bartlett MS; Smith JW; Wilde CE
Infect Immun; 1993 Apr; 61(4):1315-9. PubMed ID: 8454333
[TBL] [Abstract][Full Text] [Related]
16. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
[TBL] [Abstract][Full Text] [Related]
17. Differences exist in the immunoblotting profiles of cyst and trophozoite antigens of Pneumocystis carinii.
Chatterton JM; Joss AW; Pennington TH; Ho-Yen DO
J Med Microbiol; 1995 Feb; 42(2):120-6. PubMed ID: 7869347
[TBL] [Abstract][Full Text] [Related]
18. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.
Cushion MT; Collins M; Hazra B; Kaneshiro ES
Antimicrob Agents Chemother; 2000 Mar; 44(3):713-9. PubMed ID: 10681344
[TBL] [Abstract][Full Text] [Related]
19. Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase.
Ittarat I; Asawamahasakda W; Bartlett MS; Smith JW; Meshnick SR
Antimicrob Agents Chemother; 1995 Feb; 39(2):325-8. PubMed ID: 7726490
[TBL] [Abstract][Full Text] [Related]
20. Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Castro M
Semin Respir Infect; 1998 Dec; 13(4):296-303. PubMed ID: 9872626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
